Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 36

1.

Causal relationships among the gut microbiome, short-chain fatty acids and metabolic diseases.

Sanna S, van Zuydam NR, Mahajan A, Kurilshikov A, Vich Vila A, Võsa U, Mujagic Z, Masclee AAM, Jonkers DMAE, Oosting M, Joosten LAB, Netea MG, Franke L, Zhernakova A, Fu J, Wijmenga C, McCarthy MI.

Nat Genet. 2019 Feb 18. doi: 10.1038/s41588-019-0350-x. [Epub ahead of print]

PMID:
30778224
2.

Gut microbiota composition and functional changes in inflammatory bowel disease and irritable bowel syndrome.

Vich Vila A, Imhann F, Collij V, Jankipersadsing SA, Gurry T, Mujagic Z, Kurilshikov A, Bonder MJ, Jiang X, Tigchelaar EF, Dekens J, Peters V, Voskuil MD, Visschedijk MC, van Dullemen HM, Keszthelyi D, Swertz MA, Franke L, Alberts R, Festen EAM, Dijkstra G, Masclee AAM, Hofker MH, Xavier RJ, Alm EJ, Fu J, Wijmenga C, Jonkers DMAE, Zhernakova A, Weersma RK.

Sci Transl Med. 2018 Dec 19;10(472). pii: eaap8914. doi: 10.1126/scitranslmed.aap8914.

PMID:
30567928
3.

The Experience Sampling Method-Evaluation of treatment effect of escitalopram in IBS with comorbid panic disorder.

Vork L, Mujagic Z, Drukker M, Keszthelyi D, Conchillo JM, Hesselink MAM, van Os J, Masclee AAM, Leue C, Kruimel JW.

Neurogastroenterol Motil. 2019 Jan;31(1):e13515. doi: 10.1111/nmo.13515. Epub 2018 Nov 20.

PMID:
30460734
4.

Development, content validity, and cross-cultural adaptation of a patient-reported outcome measure for real-time symptom assessment in irritable bowel syndrome.

Vork L, Keszthelyi D, Mujagic Z, Kruimel JW, Leue C, Pontén I, Törnblom H, Simrén M, Albu-Soda A, Aziz Q, Corsetti M, Holvoet L, Tack J, Rao SS, van Os J, Quetglas EG, Drossman DA, Masclee AAM.

Neurogastroenterol Motil. 2018 Mar;30(3). doi: 10.1111/nmo.13244. Epub 2017 Nov 6.

PMID:
29106029
5.

Lactobacillus plantarum Strains Can Enhance Human Mucosal and Systemic Immunity and Prevent Non-steroidal Anti-inflammatory Drug Induced Reduction in T Regulatory Cells.

de Vos P, Mujagic Z, de Haan BJ, Siezen RJ, Bron PA, Meijerink M, Wells JM, Masclee AAM, Boekschoten MV, Faas MM, Troost FJ.

Front Immunol. 2017 Aug 23;8:1000. doi: 10.3389/fimmu.2017.01000. eCollection 2017.

6.

Rome III vs Rome IV criteria for irritable bowel syndrome: A comparison of clinical characteristics in a large cohort study.

Vork L, Weerts ZZRM, Mujagic Z, Kruimel JW, Hesselink MAM, Muris JWM, Keszthelyi D, Jonkers DMAE, Masclee AAM.

Neurogastroenterol Motil. 2018 Feb;30(2). doi: 10.1111/nmo.13189. Epub 2017 Aug 14.

PMID:
28804974
7.

Habitual diet and diet quality in Irritable Bowel Syndrome: A case-control study.

Tigchelaar EF, Mujagic Z, Zhernakova A, Hesselink MAM, Meijboom S, Perenboom CWM, Masclee AAM, Wijmenga C, Feskens EJM, Jonkers DMAE.

Neurogastroenterol Motil. 2017 Dec;29(12). doi: 10.1111/nmo.13151. Epub 2017 Jul 17.

PMID:
28714091
8.

Biomarkers for visceral hypersensitivity in patients with irritable bowel syndrome.

Mujagic Z, Jonkers DMAE, Ludidi S, Keszthelyi D, Hesselink MA, Weerts ZZRM, Kievit RN, Althof JF, Leue C, Kruimel JW, van Schooten FJ, Masclee AAM.

Neurogastroenterol Motil. 2017 Dec;29(12). doi: 10.1111/nmo.13137. Epub 2017 Jul 3.

PMID:
28675524
9.

Use of Rome criteria for the diagnosis of irritable bowel syndrome in primary care: a survey among European countries.

Mujagic Z, Jonkers DMAE, Hungin APS, de Wit NJ, Wensaas KA, Palka M, Leeters V, Kruimel JW, Leue C, Masclee AAM, Muris JWM.

Eur J Gastroenterol Hepatol. 2017 Jun;29(6):651-656. doi: 10.1097/MEG.0000000000000848.

PMID:
28125426
10.

The effects of Lactobacillus plantarum on small intestinal barrier function and mucosal gene transcription; a randomized double-blind placebo controlled trial.

Mujagic Z, de Vos P, Boekschoten MV, Govers C, Pieters HH, de Wit NJ, Bron PA, Masclee AA, Troost FJ.

Sci Rep. 2017 Jan 3;7:40128. doi: 10.1038/srep40128.

11.

The effect of host genetics on the gut microbiome.

Bonder MJ, Kurilshikov A, Tigchelaar EF, Mujagic Z, Imhann F, Vila AV, Deelen P, Vatanen T, Schirmer M, Smeekens SP, Zhernakova DV, Jankipersadsing SA, Jaeger M, Oosting M, Cenit MC, Masclee AA, Swertz MA, Li Y, Kumar V, Joosten L, Harmsen H, Weersma RK, Franke L, Hofker MH, Xavier RJ, Jonkers D, Netea MG, Wijmenga C, Fu J, Zhernakova A.

Nat Genet. 2016 Nov;48(11):1407-1412. doi: 10.1038/ng.3663. Epub 2016 Oct 3.

PMID:
27694959
12.

A novel biomarker panel for irritable bowel syndrome and the application in the general population.

Mujagic Z, Tigchelaar EF, Zhernakova A, Ludwig T, Ramiro-Garcia J, Baranska A, Swertz MA, Masclee AA, Wijmenga C, van Schooten FJ, Smolinska A, Jonkers DM.

Sci Rep. 2016 Jun 6;6:26420. doi: 10.1038/srep26420.

13.

Volatile organic compounds in breath as markers for irritable bowel syndrome: a metabolomic approach.

Baranska A, Mujagic Z, Smolinska A, Dallinga JW, Jonkers DM, Tigchelaar EF, Dekens J, Zhernakova A, Ludwig T, Masclee AA, Wijmenga C, van Schooten FJ.

Aliment Pharmacol Ther. 2016 Jul;44(1):45-56. doi: 10.1111/apt.13654. Epub 2016 May 2.

14.

Population-based metagenomics analysis reveals markers for gut microbiome composition and diversity.

Zhernakova A, Kurilshikov A, Bonder MJ, Tigchelaar EF, Schirmer M, Vatanen T, Mujagic Z, Vila AV, Falony G, Vieira-Silva S, Wang J, Imhann F, Brandsma E, Jankipersadsing SA, Joossens M, Cenit MC, Deelen P, Swertz MA; LifeLines cohort study, Weersma RK, Feskens EJ, Netea MG, Gevers D, Jonkers D, Franke L, Aulchenko YS, Huttenhower C, Raes J, Hofker MH, Xavier RJ, Wijmenga C, Fu J.

Science. 2016 Apr 29;352(6285):565-9. doi: 10.1126/science.aad3369. Epub 2016 Apr 28.

15.

Editorial: serotonin and irritable bowel syndrome--reconciling pharmacological effects with basic biology; authors' reply.

Mujagic Z, Keszthelyi D, Thijssen AY, Jonkers DM, Masclee AA.

Aliment Pharmacol Ther. 2016 Mar;43(5):646-7. doi: 10.1111/apt.13506. No abstract available.

16.

Proton pump inhibitors affect the gut microbiome.

Imhann F, Bonder MJ, Vich Vila A, Fu J, Mujagic Z, Vork L, Tigchelaar EF, Jankipersadsing SA, Cenit MC, Harmsen HJ, Dijkstra G, Franke L, Xavier RJ, Jonkers D, Wijmenga C, Weersma RK, Zhernakova A.

Gut. 2016 May;65(5):740-8. doi: 10.1136/gutjnl-2015-310376. Epub 2015 Dec 9.

17.

Update on pathogenesis and predictors of response of therapeutic strategies used in inflammatory bowel disease.

Quetglas EG, Mujagic Z, Wigge S, Keszthelyi D, Wachten S, Masclee A, Reinisch W.

World J Gastroenterol. 2015 Nov 28;21(44):12519-43. doi: 10.3748/wjg.v21.i44.12519. Review.

18.

Alterations in serotonin metabolism in the irritable bowel syndrome.

Thijssen AY, Mujagic Z, Jonkers DM, Ludidi S, Keszthelyi D, Hesselink MA, Clemens CH, Conchillo JM, Kruimel JW, Masclee AA.

Aliment Pharmacol Ther. 2016 Jan;43(2):272-82. doi: 10.1111/apt.13459. Epub 2015 Nov 5.

19.

Cohort profile: LifeLines DEEP, a prospective, general population cohort study in the northern Netherlands: study design and baseline characteristics.

Tigchelaar EF, Zhernakova A, Dekens JA, Hermes G, Baranska A, Mujagic Z, Swertz MA, Muñoz AM, Deelen P, Cénit MC, Franke L, Scholtens S, Stolk RP, Wijmenga C, Feskens EJ.

BMJ Open. 2015 Aug 28;5(8):e006772. doi: 10.1136/bmjopen-2014-006772.

20.

Systematic review: instruments to assess abdominal pain in irritable bowel syndrome.

Mujagic Z, Keszthelyi D, Aziz Q, Reinisch W, Quetglas EG, De Leonardis F, Segerdahl M, Masclee AA.

Aliment Pharmacol Ther. 2015 Nov;42(9):1064-81. doi: 10.1111/apt.13378. Epub 2015 Aug 20. Review.

21.

Volatile Organic Compounds in Exhaled Air as Novel Marker for Disease Activity in Crohn's Disease: A Metabolomic Approach.

Bodelier AG, Smolinska A, Baranska A, Dallinga JW, Mujagic Z, Vanhees K, van den Heuvel T, Masclee AA, Jonkers D, Pierik MJ, van Schooten FJ.

Inflamm Bowel Dis. 2015 Aug;21(8):1776-85. doi: 10.1097/MIB.0000000000000436.

PMID:
26199990
22.

The Experience Sampling Method--a new digital tool for momentary symptom assessment in IBS: an exploratory study.

Mujagic Z, Leue C, Vork L, Lousberg R, Jonkers DM, Keszthelyi D, Hesselink MA, van Schagen TJ, van Os J, Masclee AA, Kruimel JW.

Neurogastroenterol Motil. 2015 Sep;27(9):1295-302. doi: 10.1111/nmo.12624. Epub 2015 Jun 22.

PMID:
26100684
23.

Small intestinal permeability is increased in diarrhoea predominant IBS, while alterations in gastroduodenal permeability in all IBS subtypes are largely attributable to confounders.

Mujagic Z, Ludidi S, Keszthelyi D, Hesselink MA, Kruimel JW, Lenaerts K, Hanssen NM, Conchillo JM, Jonkers DM, Masclee AA.

Aliment Pharmacol Ther. 2014 Aug;40(3):288-97. doi: 10.1111/apt.12829. Epub 2014 Jun 18.

24.

Markers for visceral hypersensitivity in patients with irritable bowel syndrome.

Ludidi S, Mujagic Z, Jonkers D, Keszthelyi D, Hesselink M, Kruimel J, Conchillo J, Masclee A.

Neurogastroenterol Motil. 2014 Aug;26(8):1104-11. doi: 10.1111/nmo.12365. Epub 2014 Jun 11.

PMID:
24920528
25.

Management of neck metastases of unknown primary origin united in two European centers.

Straetmans J, Vent J, Lacko M, Speel EJ, Huebbers C, Semrau R, Hoebers F, Mujagic Z, Klussmann JP, Preuss SF, Kremer B.

Eur Arch Otorhinolaryngol. 2015 Jan;272(1):195-205. doi: 10.1007/s00405-014-2934-5. Epub 2014 Mar 11.

PMID:
24615648
26.

Vascular endothelial growth factor receptor-1 expression in breast cancer and its correlation to vascular endothelial growth factor a.

Srabovic N, Mujagic Z, Mujanovic-Mustedanagic J, Softic A, Muminovic Z, Rifatbegovic A, Begic L.

Int J Breast Cancer. 2013;2013:746749. doi: 10.1155/2013/746749. Epub 2013 Dec 12.

27.

Interleukin 13 expression in the primary breast cancer tumour tissue.

Srabovici N, Mujagic Z, Mujanovic-Mustedanagic J, Muminovic Z, Softic A, Begic L.

Biochem Med (Zagreb). 2011;21(2):131-8.

28.

Interleukin 18 expression in the primary breast cancer tumour tissue.

Srabović N, Mujagić Z, Mujanović-Mustedanagić J, Muminović Z, Cickusić E.

Med Glas (Zenica). 2011 Feb;8(1):109-15.

PMID:
21263407
29.
30.

Circulating levels of prolactin in breast cancer patients.

Mujagić Z, Mujagić H, Prnjavorac B.

Med Arh. 2005;59(1):33-5.

PMID:
15822682
31.

Importance of serum prolactin determination in metastatic breast cancer patients.

Mujagić Z, Mujagić H.

Croat Med J. 2004 Apr;45(2):176-80.

32.

Alcohol in alcoholic liver disease is a causative factor for development of allergic skin manifestations.

Mujagić H, Prnjavorac B, Mujagic Z, Festa G.

Med Arh. 2003;57(5-6):273-8.

PMID:
15022578
33.

[Correlation of body mass index and aminotransferase activity in healthy adolescents].

Zunić L, Begić L, Mujagić Z, Prnjavorac B, Zildzić M, Mulaomerović A.

Med Arh. 2003;57(5-6):267-8. Bosnian.

PMID:
15022576
35.

Mechanisms of action and potential therapeutic uses of thalidomide.

Mujagić H, Chabner BA, Mujagić Z.

Croat Med J. 2002 Jun;43(3):274-85. Review.

Supplemental Content

Loading ...
Support Center